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SPECIAL REPORT
UKCCCR guidelines for the welfare of animals
in experimental neoplasia
Prepared for the UKCCCR by an ad hoc committee comprising:
P. Workman (MRC Clinical Oncology Unit, Cambridge, Chairman); A. Balmain (Beatson
Institute for Cancer Research, Glasgow); J.A. Hickman (CRC Experimental Cancer Chemo-
therapy Group Research, Aston); N.J. McNally (deputy, A.M. Rohas, both CRC Gray
Laboratory, Northwood); N.A. Mitchison (University College, London); C.G. Pierrepoint
(Tenovus Institute, Cardiff); R. Raymond (ICRF, London); C. Rowlatt (ICRF, London); T.C.
Stephens (ICI Pharmaceuticals, Alderley Park, Macclesfield); and J. Wallace (Institute of Cancer
Research, London). Observer: D.W. Straughan (Home Office).
Background and scope
Animals with local or disseminated tumours are likely to
experience pain and/or distress, thus justifying special care
and attention from licensees and others involved in their
welfare. Associated techniques including surgical prep-
aration, irradiation, and drug administration may increase
the severity of an experimental procedure. Recognizing this,
the United Kingdom Coordinating Committee on Cancer
Research (UKCCCR*), representing the main cancer chari-
ties and the MRC, has prepared the following guidelines for
research workers using animals in experimental neoplasia.
Particular emphasis is focussed on the prediction and recog-
nition of adverse effects and the implementation of humane
end points. The majority of work in this area utilises small
laboratory animals, particularly rodents. Consequently we
have drawn largely on available expertise with these species.
However, the general principles are applicable to all species
of animal.
While we recognize and encourage the development of
alternative research techniques which do not involve animals,
we consider that there are many questions which can be
answered only by the study of tumours growing in vivo. The
general welfare of laboratory animals and the performance
of regulated procedures upon them are both covered by the
Animals (Scientific Procedures) Act (1986) effective from 1
January 1987. Under this Act all scientific procedures in
living vertebrates which may have the effect of causing pain,
suffering, distress or lasting harm are controlled by the
Home Office and require specific authority through Personal
and Project Licences. Recommendations for the housing and
care of laboratory animals are specified in the Royal Society/
UFAW Guidelines (Part 1, 1987). In addition, the following
references are recommended for advice on general animal
husbandry and experimental techniques: Gay (1965),
Fowler (1978), Tuffery (1987) and the Institute of Animal
Technology (in press).
We welcome the new Act and the Royal Society/UFAW
Guidelines, and look forward to the publication of further
guidelines from expert sources. We envisage that the present
guidelines will be of general value to workers carrying out
experiments which involve the growth of tumours in experi-
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mental animals, whether these arise spontaneously, are pro-
duced by transplantation (including passage and
hybridomas), or are induced by carcinogenic agents or
genetic manipulation. They may be especially helpful in the
completion of Project Licence Applications, in particular
section 19b (v and vi) which requires that applicants list the
possible adverse effects and their likely incidence as well as
the proposed methods of controlling severity, e.g. the use of
analgesia, regional or local anaesthesia and sedation, and the
implementation of humane end points.
It is an important feature of the present guidelines that the
procedures practised upon animals in cancer research, and
particularly the humane end points used, should be subject
to a continuous process of refinement. The guidelines will
therefore be modified and updated as appropriate. The
guidelines are not mandatory. The term 'should' is used to
encourage attainment of desirable standards; the term 'must'
is used only where legal obligations apply.
The Recommendations are divided into two parts. The
General Recommendations are applicable to all regulated
procedures. The Specific Recommendations are more directly
targeted to the particular problems of experimental neo-
plasia. It is important to emphasize that procedural guide-
lines, especially with respect to implementation of humane
end points, must be tailored to the precise nature of each
individual experimental neoplasia model. To illustrate this,
the Appendix gives some examples of criteria for particular
tumour systems.
Recommendations
General recommendations
1. The following recommendations are based on the
premise that for each study those involved in the procedures
will weigh the likely adverse effects on the animals used
against the benefits likely to accrue from the work. The
potential benefits of cancer research are clear. Nevertheless,
the feasibility of using alternative methods not involving live
animals should be considered. In vitro cell lines may be
appropriate in many instances.
2. Where animals must be used, the degree of pain and
distress must be minimised by judicious use of anaesthetics
and analgesics, the refinement of experimental techniques,
and the early implementation of humane end points. Licen-
sees must know the severity band for each regulated pro-
cedure (i.e. mild, moderate, substantial or unclassified). The
severity band will have been arrived at by agreement
between the applicant and the Home Office and takes into
consideration details of the procedure itself, the nature and
incidence of any likely adverse effects and any practical
measures which will be used to minimise severity. The
severity condition of Personal and Project Licences requires
a Personal Licensce to notify thc Procject Licence holder if
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one or more severity bands may have been or are likely to
be exceeded. The Project Licence holder must notify the
Home Office Inspectorate of this at the earliest possible
opportunity. In addition, there is an inviolable termination
condition in every Personal Licence, which requires the
Personal Licensee to ensure the immediate killing (by an
approved painless method) of any animal in severe pain or
severe distress which cannot be alleviated.
3. Where certain procedures cause particular concern, these
must be noted specifically in the Project Licence application.
A more detailed justification and definition of severity limits
will be needed. Such procedures may be subject to additional
conditions in the Personal Licence to control numbers of
animals and/or severity. In addition, the Home Office may
require particular reports on them.
4. It is important that pilot experiments should be under-
taken on small numbers of animals before new procedures
are carried out on a larger scale. The pilot experiments
should identify particular problems, define the time scale of
critical events, and help to refine the appropriate end point.
In all experiments the numbers of animals used should be
restricted to the minimum consistent with the design and
purpose of the experiment.
5. All involved staff should be aware of their individual
responsibilities and a clear chain of consultation should be
established. The decision-making process should be designed
so that under all circumstances appropriate action is taken
promptly to deal with any problems which may arise, for
example if the clinical condition of a tumour-bearing animal
deteriorates unexpectedly or if the individual effects of
tumour and therapeutic treatment are difficult to distinguish
(see section 3.5).
6. All involved staff should receive appropriate training
and supervision. Where research workers are using unfami-
liar procedures, information and guidance should be
obtained from experienced colleagues, as well as from the
scientific literature.
Specific recommendations
1. Assessment of severity
1.1 Before assessing the severity of any regulated procedure
on the well-being of an animal it is essential that the
observer is familiar with the normally accepted behav-
iour, anatomy, physiology and environmental require-
ments of the species used, for example growth rate,
dietary intake and microbial status.
1.2 Particular attention should be paid to those body
systems most likely to be affected by the procedure.
With solid tumours this will include ulceration, disten-
sion of covering tissues and cachexia. In the case of
ascitic tumours, abdominal distension, anaemia and
cachexia will be important. Lymphatic involvement
from lymphoma and neurological disturbance from
intracerebral tumours are examples of special compli-
cations arising in specific situations.
1.3 Certain deviations from normal well-being may be
difficult to observe, for example induction of anaemia
or the development of metastases, and special investi-
gations may be required to detect them.
1.4 Appropriate control animals should always be included,
so that the individual effects of the tumour and of any
treatment can be distinguished.
2. Biology of tumours
2.1 Due consideration should be given to the known
biology of the tumour. For spontaneous and trans-
planted tumours important features will include growth
rate, invasion, distension, ulceration, metastases, site,
and production of cachectic factors.
2.2 In the case of tumours induced by carcinogens, viruses
or genetic manipulation, factors such as method of
induction may affect the nature and location of result-
ing tumours.
2.3 Contamination of tumour cell lines with viruses and
other micro-organisms may compromise experimental
results, as well as causing an outbreak of disease
among laboratory animals. Screening of cell lines for
rodent viruses is strongly recommended. For example,
Sendai virus is often used to induce cell fusion in vitro
and is pathogenic to mice and rats. A potential hazard
exists for research workers from immune-compromised
animals receiving human tumour xenografts which may
be contaminated with human pathogens. In such cases,
special facilities should be considered for both tissue
preparation and animal containment (e.g. flexible film
isolators) (see UKCCCR Guidelines for the Xenograft-
ing of Human Tumours, 1980).
3. Humane end points
3.1 Considerable care should be given to the judicious
choice of end point for tumour growth. This should
take into account predictable indications of pain, dis-
tress or significant deviation from normal behaviour.
Unless specified otherwise on the Project Licence, ani-
mals should be killed before:
(i) predictable death occurs;
(ii) they get into poor condition;
(iii) the tumour mass becomes over-large, likely to
ulcerate or unacceptably limits normal behaviour.
3.2 In the case of local solid tumours, the required infor-
mation on response to therapy may be obtained by
tumour regrowth delay or clonogenic assay, rather than
by tumour weight at a given time. Difficulties may arise
with this last method because optimum shrinkage of
treated tumours may not be achieved before control
tumours become excessively large and/or distressing to
the host animal. Where such an assay has to be used,
the tumour burden should be regulated as indicated in
section 3.1.
3.3 The choice of site for solid tumours also requires
considerable care, and particular attention should be
given to avoidance of sites involving the special senses
or where the capacity for tumour growth is limited.
Subcutaneous or intradermal growth on the back or in
the flank are considered to cause the least distress,
while tumours implanted in the footpad, tail, brain and
eye will require much greater justification. Distension
of musculature is generally painful and this should be
considered with intramuscular implants. Extra attention
must be paid if multiple sites are used.
3.4 The survival end point should be avoided wherever
possible, and its use will require special justification.
Where this end point has to be used for animals with
ascites or disseminated tumours, particular care should
be taken. It is in general unacceptable to wait for
predictable death. Animals expected shortly to become
moribund should be killed, unless specified otherwise in
the Project Licence.
3.5 Difficulties may occur where the effects of anticancer
agents on tumour growth are being evaluated. The high
toxicity of these agents may combine with the adverse
effects of the tumour, but this might be justified by the
prospect of a therapeutic remission (as occurs in man).
Thus the outcome of such experiments may be un-
certain, and uncritical culling would frustrate the
purpose of the study. However, where the outcome can
be reasonably predicted, animals about to become
moribund should be killed.
3.6 No precise quantitative guide can be given as to the
acceptable upper limit of tumour burden, since the
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of the tumour, the site and mode of growth, and the
nature of associated treatments. However, tumour
burden should not usually exceed 10% of the host
animal's normal body weight. It should be emphasized,
however, that problems may arise with much smaller
tumour burdens.
3.7 With ascitic tumours, including hybridomas, care
should be taken to ensure that the volume of ascitic
fluid does not become excessive, causing gross abdomi-
nal distension, and that solid deposits and cachexia are
not allowed to become clinically significant. Ascitic
volumes should not usually exceed 20% of normal
body weight in mice and rats. Retired breeders are
advantageous for monoclonal antibody production,
since their abdominal musculature more readily allows
larger ascites volumes to be tolerated without discom-
fort. Ascitic tumours should normally be drained only
once. This will minimise the development of solid
tumour deposits, bleeding into the peritoneal cavity and
cachexia, as well as reducing the risk of introducing an
infection. General anaesthesia should always be
employed.
3.8 In tumour therapy experiments with adult rodents, it is
recommended that weight loss should not normally
exceed 20% of the host body weight at the commence-
ment of the experiment. For younger animals, failure to
maintain the weight gain seen in untreated control
animals should be considered as an indication of
toxicity.
3.9 Care should be taken that general housing conditions
are appropriate to the known or anticipated condition
of the tumour-bearing animal, for example in terms of
appropriate bedding, cage structure and accessibility of
food and water.
3.10 Humane end points and other procedures should be
refined in the light of experience.
4. Examination of animals
4.1 The frequency with which animals must be inspected
for signs of pain or distress and the extent of each
examination will be dictated by:
(i) the known biology of the tumour and/or the
effects of the inducing agent;
(ii) the effects of any associated techniques;
(iii) the changing clinical status of the animal.
4.2 Rapidly growing or invasive tumours will require more
frequent attention, and greater care will be required as
the tumour burden increases.
4.3 As a minimum, every tumour-bearing animal should be
inspected daily and additional more detailed exami-
nations undertaken as appropriate. The frequency of
the latter should be increased during critical periods
where the potential for animal suffering may be antici-
pated. The experimental design should ensure that these
do not occur when staff are absent. Particular attention
should be given to animals in poor health.
4.4 Appropriate assessment techniques will include: evalu-
ation of overall clinical condition, including appear-
ance, posture, body temperature, behaviour and
physiological responses; assessment of food and water
intake; weighing to determine changes in body weight
(both positive and negative changes compared to
controls can be associated with increasing tumour
burden); measurements to determine tumour volume or
mass; and inspection and palpation to locate the sites
of tumour growth, as well as to assess distension,
ulceration and compromised mobility.
4.5 Other special examination techniques will be more
valuable for specific sites, e.g. breathing rate for lung
deposits, neurological disturbance for brain neoplasms,
and blood cell counts for leukaemias. Laparotomy or
endoscopy may be appropriate in some instances. Esti-
mation of circulating tumour marker substances may
also be of value. Autopsy of animals may expose
adverse effects undetected by external examinations.
5. Documentation and publication
5.1 Researchers are strongly urged, for each tumour model
in use in their laboratory, to document the expected
behaviour of the tumour and host animal under vari-
ous experimental conditions, including therapy. They
should also document humane end points to limit
severity with regard to acute and delayed toxicity and
maximal tumour burden, and indicate any particular
problems which may be encountered in the use of each
model. The appropriate response to such problems
should be described and the chain of consultation and
responsibility clearly defined. Consideration should be
given to the inclusion of a numerical scoring system to
facilitate decision-making, e.g. when to contact senior
staff or to kill an animal. The guidelines for specific
tumour models should be readily available to and
agreed between all research and animal husbandry staff
involved with that model. Particular care should be
taken that all procedures are understood by junior and
occasional staff. Researchers are also encouraged to
share this information with other groups using the
same system, for example when providing a tumour cell
line to another laboratory.
5.2 Researchers are encouraged to publish improvements in
humane end points in appropriate journals, so as to
ensure wide dissemination of the information.
5.3 Encouragement is given to incorporate animal welfare
statements into experimental protocols, and in addition
to report compliance with these and other appropriate
guidelines (including any local ones) when publishing
results. Certain journals require this (e.g. the British
Journal of Radiology, Cancer Research, and the Jour-
nal of the National Cancer Institute).
Summary and concluding remarks
Researchers have a legal and ethical responsibility to
consider the welfare of experimental animals in their care.
They must decide whether the use of animals is necessary to
answer a particular question, and if so minimise the pain
and distress involved. Studies in experimental neoplasia
present particular problems. Workers should possess adequate
knowledge of the animals and tumour systems to be used.
Where unfamiliar procedures are to be employed, infor-
mation and guidance should be obtained through consul-
tation with experienced colleagues and from the scientific
literature. Workers should receive appropriate training and
supervision. Pilot experiments should be carried out with
small numbers of animals, and numbers should always be
restricted to the minimum consistent with the design and
purpose of the experiment. Tumour end points should be
chosen and refined so as to minimise the adverse effects on
the host animal. Survival end points are discouraged. In
most instances animals should be killed before they become
moribund. Repeated draining of ascitic tumours is discour-
aged, and a general anaesthetic should be used. All staff
should understand their individual responsibilities, and a
clear chain of consultation should be established so that
prompt action can be taken to deal with any problems that
arise. Finally, researchers are encouraged to refine end points
in experimental neoplasia and to publish such improvements,
to incorporate welfare statements in experimental protocols,
and to report compliance with appropriate guidelines in
publications.112 UKCCCR GUIDELINES ON ANIMAL WELFARE
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Appendix
The following examples of tumour systems are given for
illustration.
1. RIF-] mouse sarcoma. This is a transplantable sarcoma
of C3H/Km mice which is widely used in radiation
and chemotherapy studies (Twentyman, et al., J.
Natl Cancer Inst., 64, 595, 1980). It can be maintained
in cell culture and is grown in vivo as a solid tumour
by implantation intradermally in the skin of the flank
or intramuscularly in the hind leg. The end points used
to determine therapeutic effects on the solid tumour
are clonogenic survival, regrowth delay and tumour
cure. It is common practice to terminate regrowth
delay experiments with leg tumours when the limb
diameter reaches approximately 16mm. At this point
the tumour mass is -3 g or 10% of the body weight
and the host animals are in otherwise normal con-
dition. Growth delay is determined from the time to
reach four times the treatment size. Metastases occur
late and rarely.
2. DMBA-induced rat mammary1 tumour. (Huggins et il/., J.
EYp. Med., 109, 25, 1959). Setting a humane end poinit
with this tumour is more difficult. There is hetero-
geneity in both the number of tumours which develop
and in their relative growth rates, so that individual
animals may have widely differing tumour burdens.
Close daily monitoring is essential and an overall
judgement must be made, based on the aggregate
tumour mass, the size and condition of larger tumours
and the general health of the animal. While animals
may tolerate an aggregate tumour burden of > 10% of
body weight if there are many small tumours, a singlc
large tumour can lead to rapid deterioration necessitat-
ing humane killing of the animal.
3. MAC 16 mouse colonic adenocarcinoma. This is a trans-
plantable tumour of NMRI mice which is normally
grown subcutaneously in the flank (Bibby, et al.,
J. Nati Cancer Inst., 78, 539, 1987). It is of particular
interest because it causes progressive cachexia and loss
of body weight, beginning at a tumour weight of
about 100mg in a 30g mouse and increasing over the
subsequent 7-14 days. The host mice continue to eat
normally over this period. The main difficulty in
working with the MAC 16 tumour is the heterogeneity
of cachectic response between animals with similar
tumour burdens. Because of this, individual animals
are weighed at the time of transplantation and then
daily thereafter. Mice are killed when the weight loss is
between 20 and 40% (maximum). This careful moni-
toring procedure prevents the occurrence of death due
to cachexia.
4. L1210 mouse leukaemia. This is normally grown as an
ascites tumour and used for the evaluation of anti-
cancer agents (Geran et al., Cancer Chemother.
Rep., 3, 1, 1972). The difficulties associated with this
model are also shared by other ascites tumour models
for which the survival end point has been widely used
in the past. Cells (routinely 105-106) are injected into
the peritoneal cavity of C57BL x DBA/2F1 (BD2F1)
mice. A direct relationship normally exists between the
number of viable L1210 cells injected, or remaining
after drug treatment, and the subsequent survival of
the animal. Implantation of 105 L1210 cells, with a
doubling time of approximately 12 hours in exponen-
tial growth, has been shown to produce life-threaten-
ing symptoms by the eighth day after implantation.
These symptoms are manifested as a marked abdomi-
nal distension produced by peritoneal ascitic fluid,
dyspnoea, a hunched posture and poor coat quality,
particularly a ruffling of the fur, and mild catatonia.
As animals approach this phase of tumour growth,
twice daily inspection of tumour-bearing animals is
necessary to assess morbidity. The therapeutic sub-
stance under investigation is normally administered 24
hours after the implantation of the tumour, and may
be given at subsequent times. However, the protocol
may be modified so as to avoid possible temporal
overlap of the toxicity of the substance and the
symptoms of morbidity induced by the tumour.
5. Rodent tumour metastasis models. Metastasis may be
seeded either 'artificially' by intravenous injection of
tumour cells, or spontaneously after growth of a solid
deposit which can be removed surgically when appro-
priate. Such models include the B16 and other melano-
mas and UV-induced fibrosarcomas in mice (Kripke
et al., Cancer Res., 38, 2962, 1978). It may not be
necessary to wait until mice develop symptoms of
impending morbidity, and the required information
may be obtained after humane killing at an earlier
stage (see Kripke et al., cited above). Special attention
should be directed to detecting signs associated with
clinically significant disease in sites particularly sus-
ceptible to metastasis, e.g. dyspnoea due to lung
deposits.
6. Chemically-induced colonic tumours in rats. Tumours of
certain internal organs are difficult to detect by exter-
nal examination. As an example of the use of special
diagnostic techniques, colonic tumours in rats can be
identified by endoscopic examination (Merz et al.,
Hepato-Gastroenterol, 28, 53, 1981; Hermanek &
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7. Neoplasia in transgenic animals. Problems may be encoun-
tered when oncogenes are inserted or activated, or
indeed other genetic alterations are introduced into
recipient transgenic animals. In particular it may be
difficult to predict the consequences of such genetic
changes, which may occur other than in the particular
organ of interest. An example of this occurred in
transgenic mice carrying a hybrid gene comprising the
murine a A-crystallin promoter fused to the coding
sequence of the oncogene SV40 T antigen. Not only
did the expected lens tumours develop, but in addition
several animals developed non-lenticular tumours at
various sites throughout the body (Mahon et al.,
Science, 235, 1622, 1987). Thus special care must be
taken to ensure that such associated sequelae are
identified and appropriate measures taken.